AGL 39.55 Decreased By ▼ -0.45 (-1.13%)
AIRLINK 128.59 Decreased By ▼ -0.47 (-0.36%)
BOP 6.85 Increased By ▲ 0.10 (1.48%)
CNERGY 4.71 Increased By ▲ 0.22 (4.9%)
DCL 8.41 Decreased By ▼ -0.14 (-1.64%)
DFML 41.05 Increased By ▲ 0.23 (0.56%)
DGKC 82.01 Increased By ▲ 1.05 (1.3%)
FCCL 33.05 Increased By ▲ 0.28 (0.85%)
FFBL 74.03 Decreased By ▼ -0.40 (-0.54%)
FFL 11.90 Increased By ▲ 0.16 (1.36%)
HUBC 110.15 Increased By ▲ 0.57 (0.52%)
HUMNL 14.12 Increased By ▲ 0.37 (2.69%)
KEL 5.21 Decreased By ▼ -0.10 (-1.88%)
KOSM 7.50 Decreased By ▼ -0.22 (-2.85%)
MLCF 39.10 Increased By ▲ 0.50 (1.3%)
NBP 63.70 Increased By ▲ 0.19 (0.3%)
OGDC 193.30 Decreased By ▼ -1.39 (-0.71%)
PAEL 25.56 Decreased By ▼ -0.15 (-0.58%)
PIBTL 7.30 Decreased By ▼ -0.09 (-1.22%)
PPL 153.10 Decreased By ▼ -2.35 (-1.51%)
PRL 25.91 Increased By ▲ 0.12 (0.47%)
PTC 17.51 Increased By ▲ 0.01 (0.06%)
SEARL 81.10 Increased By ▲ 2.45 (3.12%)
TELE 7.67 Decreased By ▼ -0.19 (-2.42%)
TOMCL 33.44 Decreased By ▼ -0.29 (-0.86%)
TPLP 8.44 Increased By ▲ 0.04 (0.48%)
TREET 16.35 Increased By ▲ 0.08 (0.49%)
TRG 56.70 Decreased By ▼ -1.52 (-2.61%)
UNITY 27.55 Increased By ▲ 0.06 (0.22%)
WTL 1.37 Decreased By ▼ -0.02 (-1.44%)
BR100 10,515 Increased By 69.4 (0.66%)
BR30 31,123 Decreased By -66.3 (-0.21%)
KSE100 98,312 Increased By 513.4 (0.52%)
KSE30 30,683 Increased By 202.5 (0.66%)

Acacia Pharma, a specialist in finding new uses for existing medicines or "repurposing" them, said on Monday it planned to float in London, marking a further boost for British pharmaceutical and biotech fundraising.
One person familiar with the plan said the aim was to raise up to around 150 million pounds ($230 million). That would make it the second-biggest pharma initial public offering (IPO) in London since 2005, behind the 200 million pounds raised by Circassia Pharmaceuticals last year.
Acacia, founded in Cambridge, England in 2007, said it expected its shares to start trading on the main market of the London Stock Exchange in October.
It has four drugs that have demonstrated success in mid-stage clinical trials. The most advanced, APD421, is currently being evaluated in final Phase III studies for the management of post-operative nausea and vomiting.
The firm's IPO move follows plans announced last week by Britain's Shield Therapeutics and Finland's Faron Pharmaceuticals to also float in London.

Copyright Reuters, 2015

Comments

Comments are closed.